Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Tumor Lysis Syndrome
Scott C. Howard, Deborah P. Jones, Ching‐Hon Pui
New England Journal of Medicine (2011) Vol. 364, Iss. 19, pp. 1844-1854
Open Access | Times Cited: 910

Showing 1-25 of 910 citing articles:

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 7, pp. 617-629
Open Access | Times Cited: 2001
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts, Matthew S. Davids, John M. Pagel, et al.
New England Journal of Medicine (2015) Vol. 374, Iss. 4, pp. 311-322
Open Access | Times Cited: 1734
Cytokine release syndrome
Alexander Shimabukuro‐Vornhagen, Philipp Gödel, Marion Subklewe, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 1423
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek, Bruce D. Cheson, Daniel Catovsky, et al.
Blood (2018) Vol. 131, Iss. 25, pp. 2745-2760
Open Access | Times Cited: 1412
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 23, pp. 2225-2236
Open Access | Times Cited: 740
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids, Andrew W. Roberts, John F. Seymour, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 8, pp. 826-833
Open Access | Times Cited: 675
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood (2020) Vol. 135, Iss. 24, pp. 2137-2145
Open Access | Times Cited: 607
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 15, pp. 1277-1284
Open Access | Times Cited: 585
Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers
Forrest M. Kievit, Miqin Zhang
Advanced Materials (2011) Vol. 23, Iss. 36
Open Access | Times Cited: 482
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, et al.
The Lancet Oncology (2017) Vol. 19, Iss. 1, pp. 65-75
Open Access | Times Cited: 347
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Mark R. Charbonneau, Vincent M. Isabella, Ning Li, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 318
Computational Phenotype Discovery Using Unsupervised Feature Learning over Noisy, Sparse, and Irregular Clinical Data
Thomas A. Lasko, Joshua C. Denny, Mia Levy
PLoS ONE (2013) Vol. 8, Iss. 6, pp. e66341-e66341
Open Access | Times Cited: 311
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour, Shuo Ma, Danielle M. Brander, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 2, pp. 230-240
Open Access | Times Cited: 311
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 19, pp. 1973-1980
Closed Access | Times Cited: 293
Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD
Anand Srivastava, Arnaud D. Kazé, Ciaran J. McMullan, et al.
American Journal of Kidney Diseases (2017) Vol. 71, Iss. 3, pp. 362-370
Open Access | Times Cited: 259
Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations
Kristen Renee McSweeney, Laura Kate Gadanec, Tawar Qaradakhi, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1572-1572
Open Access | Times Cited: 250
Uric acid and the kidney
Sahar Fathallah-Shaykh, Monica T. Cramer
Pediatric Nephrology (2013) Vol. 29, Iss. 6, pp. 999-1008
Closed Access | Times Cited: 241
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu, Ming Yi, Shuang Qin, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 237
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 323-339
Open Access | Times Cited: 227
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V. Maus, S. Alexander, Michael R. Bishop, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001511-e001511
Open Access | Times Cited: 214
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Na Zhao, Jin Cao, Longyong Xu, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 4, pp. 1283-1299
Open Access | Times Cited: 196
Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology
Gail Jones, Andrew Will, Graham Jackson, et al.
British Journal of Haematology (2015) Vol. 169, Iss. 5, pp. 661-671
Open Access | Times Cited: 184
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G. Wierda, John N. Allan, Tanya Siddiqi, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 34, pp. 3853-3865
Open Access | Times Cited: 183
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
Brian A. Jonas, Daniel A. Pollyea
Leukemia (2019) Vol. 33, Iss. 12, pp. 2795-2804
Open Access | Times Cited: 162
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Constantine S. Tam, John N. Allan, Tanya Siddiqi, et al.
Blood (2022) Vol. 139, Iss. 22, pp. 3278-3289
Open Access | Times Cited: 154
Page 1 - Next Page

Scroll to top